The central importance of IL-17A in inflammatory conditions is illustrated by the recent approval of two monoclonal antibody therapies that inhibit interleukin-17A for treatment of psoriasis, spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis (110), although both these antibody therapies have significant side effects. Here, IL17A is linked to ankylosing spondylitis.